Whilst we have not seen any difference in a range of GI measures during TEZ/IVA compared to placebo, other published data suggest there may be value in evaluating GI function over longer periods and with triple combination CFTR modulators.In vitro studies, using intestinal organoids from individuals with CF, are supportive of the return of intestinal CFTR function with both TEZ/IVA and triple combination CFTR therapy32. Here, CFTR is linked to cystic fibrosis.